Skip to main content
S&P 5007,670.84-0.17%DOW51,349.92-0.26%NASDAQ26,797.54-0.09%GOLD$4,210.50+0.74%OIL$89.25-0.15%
Delayed
Smart Investors Daily
SE

NASDAQ · SEPN

Septerna, Inc. Common Stock

Healthcare · Biotechnology

$39.13

Down-$0.61 (-1.53%)

Updated Sep 30, 2026, 4:18 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.17B
P/E ratio
-19.76
Dividend yield
0.00%
52-week range
$17.33 – $51.10
Volume
564.5K
Avg. volume
331.52K

Price performance · SEPN

SEPN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 29, 2026

SEPN closed at $39.13 after 20 trading sessions, up 3.85% for the selected period.

Last close
$39.13
Period change
+3.85%
Period low
$36.75
Period high
$40.38
Daily close
View OHLC price history
SEPN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 29, 2026$39.52$39.565$38.37$39.13564.5K
Sep 28, 2026$37.61$39.78$37.03$39.74338.34K
Sep 25, 2026$38.34$38.34$37.35$37.77344.3K
Sep 24, 2026$38.41$38.805$37.49$38.13293.14K
Sep 23, 2026$40.17$40.17$36.98$38.45509.72K
Sep 22, 2026$38.78$41.09$38.74$40.38412.06K
Sep 21, 2026$38.97$39.47$38.01$38.54252.44K
Sep 18, 2026$39.28$39.48$37.8808$38.69448.2K
Sep 17, 2026$39.38$40.52$39.005$39.50256.83K
Sep 16, 2026$39.15$40.24$37.9175$38.44304.95K
Sep 15, 2026$39.52$39.52$38.2629$38.86269.62K
Sep 14, 2026$38.66$39.95$38.51$39.55356.04K
Sep 11, 2026$37.75$40.0199$37.56$38.51354.8K
Sep 10, 2026$37.37$38.43$36.60$37.75338.72K
Sep 9, 2026$37.15$39.40$37.15$37.97475.31K
Sep 8, 2026$36.15$38.06$36.01$37.37309.9K
Sep 4, 2026$36.57$37.59$36.57$36.75199.67K
Sep 3, 2026$37.72$38.195$36.46$36.80241.56K
Sep 2, 2026$37.96$38.86$37.245$37.50263.25K
Sep 1, 2026$38.15$38.57$37.24$37.68263.95K

Latest SEPN news

The latest Smart Investors Daily articles mentioning SEPN.

Stock researchCompany · Overview

Company

OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials

Market Activity

OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment

SEPN research

Overview

Company profile and research snapshot.

Company profile

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$28.00
Implied upside
—
Analysts
—
SEPN recent ratings
DateFirmRatingTarget
Aug 19, 2026JP MorganOverweight—
Aug 13, 2026Jones TradingBuy—
Aug 12, 2026Wells FargoOverweight—
Aug 12, 2026HC Wainwright & Co.Buy—
Aug 11, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?

Septerna (SEPN) heads into a busy conference stretch, with investor attention drawn to upcoming presentations at Wells Fargo’s 21st Annual Healthcare Conference on September 8 and Cantor Fitzgerald’s Global Healthcare Conference on September 10. At a last close of US$38.51, Septerna’s recent moves tell a mixed story, with the share price return up 2.01% over 1 day and 4.79% over 7 days, yet down 13.46% over 30 days. The year to date share price return of 37.63% and 1 year total shareholder...

Yahoo · Sep 10, 2026

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s common stock to Rajiv Patni, M.D., the Company’s newly appointed Chief Medical Officer, under the Company’s 2026 Inducement Plan (the “Inducement Plan”). The inducement grant was effective as of September 8, 2026. The award was granted as an inducement material to Dr. Patni’s employme

Yahoo · Sep 1, 2026

Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare ConferenceFireside chat on Tuesday, September 8, 2026, at 8:00 a.m. ET Cantor Global Healthcare Conference 2026Fireside chat on Thursday, September 10, 2026

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By